Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone

Anticancer Res. 2026 Feb;46(2):1153-1165. doi: 10.21873/anticanres.18018.ABSTRACTBACKGROUND/AIM: Treatment of cancers known to be positive for the nuclear progesterone receptor (nPR), e.g., breast, ovarian, and endometrial cancers with PR modulators/antagonists, e.g., mifepristone, have not shown impressive improvement in palliative or longevity benefits. In contrast, several case reports showed considerable palliation and/or extension of life using mifepristone treatment for various advanced cancers devoid of the nPR. The aim of this study was to determine whether mifepristone therapy could provide improved quality of life in a patient with breast cancer considered terminal based on extensive brain and lung metastases in which the estrogen receptor…
Origen: Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone – PubMed